Current Market Position and Price Movement
On 25 Nov 2025, Epigral's stock price touched Rs.1400, marking its lowest level in the past year. This price point is significantly below its 52-week high of Rs.2195.85, representing a decline of approximately 36.3% from that peak. Despite this, the stock outperformed its sector peers marginally today, registering a day change of 0.94%, which was 0.9% ahead of the Specialty Chemicals sector's movement.
Notably, Epigral is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning indicates sustained downward momentum over multiple time frames, underscoring the stock's current weakness relative to its historical price trends.
Broader Market Context
The broader market environment presents a contrasting picture. The Sensex opened higher at 85,008.93 points, gaining 108.22 points (0.13%) and was trading near 84,964.83 points at the time of reporting. The index remains within 0.98% of its 52-week high of 85,801.70, supported by bullish moving averages where the 50-day moving average is positioned above the 200-day moving average. Mid-cap stocks are leading the market rally, with the BSE Mid Cap index gaining 0.11% on the day.
Against this backdrop, Epigral's underperformance is more pronounced, with the stock delivering a negative return of 28.18% over the past year, while the Sensex has recorded a positive return of 6.07% during the same period.
Our latest monthly pick, this Small Cap from Oil Exploration/Refineries, is showing strong performance since announcement! See why our Investment Committee chose it after screening 50+ candidates.
- - Investment Committee approved
- - 50+ candidates screened
- - Strong post-announcement performance
Financial Performance and Profitability Trends
Epigral's financial data over recent periods highlights several areas of concern. The company’s operating profit has shown a compound annual decline of 5.49% over the last five years, indicating challenges in sustaining growth in core profitability. The operating profit to net sales ratio for the latest quarter stands at 22.53%, which is the lowest recorded in recent quarters, signalling margin pressure.
Quarterly profit after tax (PAT) has declined by 52.6% compared to the average of the previous four quarters, with the latest figure at Rs.51.22 crores. Concurrently, interest expenses for the last six months have risen sharply by 286.41%, reaching Rs.45.21 crores, which adds to the financial strain on the company.
These figures contribute to the stock’s subdued performance and reflect the challenges faced by Epigral in maintaining profitability and managing costs effectively.
Long-Term and Relative Performance
Over the last three years, Epigral has underperformed the BSE500 index, continuing a trend of below-par returns. The stock’s negative return of 28.18% over the past year contrasts with the broader market’s positive trajectory, highlighting the divergence in performance. This underperformance extends to the recent three-month period as well, reinforcing the persistent challenges faced by the company in regaining investor confidence.
Balance Sheet Strength and Efficiency Metrics
Despite the pressures on profitability, Epigral demonstrates strengths in certain financial metrics. The company’s return on capital employed (ROCE) stands at a robust 23.19%, indicating efficient utilisation of capital in generating earnings. Additionally, the debt to EBITDA ratio is relatively low at 1.34 times, suggesting a manageable debt burden and a strong ability to service liabilities.
Valuation metrics also show that Epigral is trading at a discount compared to its peers’ historical averages. The enterprise value to capital employed ratio is 2.5, with a ROCE of 19.3% supporting a fair valuation framework. Over the past year, profits have risen by 37.1%, despite the stock’s negative return, resulting in a price-to-earnings-to-growth (PEG) ratio of 0.5, which may indicate undervaluation relative to earnings growth.
Considering Epigral ? Wait! SwitchER has found potentially better options in Specialty Chemicals and beyond. Compare this small-cap with top-rated alternatives now!
- - Better options discovered
- - Specialty Chemicals + beyond scope
- - Top-rated alternatives ready
Shareholding and Sector Positioning
Epigral operates within the Specialty Chemicals industry, a sector characterised by cyclical demand and sensitivity to raw material costs. The company’s majority shareholding is held by promoters, which typically provides stability in governance and strategic direction. However, the stock’s recent price trajectory suggests that market participants are weighing the company’s financial performance heavily in their valuation assessments.
While the broader market and sector indices show resilience and positive momentum, Epigral’s stock remains under pressure, reflecting the impact of its financial results and valuation considerations.
Summary of Key Price and Performance Metrics
To summarise, Epigral’s stock price at Rs.1400 marks a significant 52-week low, down from a high of Rs.2195.85. The stock’s one-year return of -28.18% contrasts with the Sensex’s 6.07% gain over the same period. Operating profit trends and quarterly earnings reflect challenges, while balance sheet metrics such as ROCE and debt ratios indicate areas of financial strength. The stock trades below all major moving averages, signalling continued downward momentum in the near term.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
